GBA Presents: THE GREEN MARKET

:) Phew!~

Jones Soda announces Meijer distribution agreement 08:50 JSDA Jones Soda announced the addition of 210 Meijer stores in six Midwest states. The agreement adds a new marquee regional retailer to Jones Soda's portfolio. All 210 Meijer stores involved in the agreement are carrying Jones Soda's top five flavors, including Berry Lemonade, Cream Soda, Green Apple, Orange and Root Beer. More than one-third are also stocking Blue Bubble Gum Soda, Watermelon Soda, and the Company's limited-edition series of Special Release flavors that change twice a year. Meijer also has the option to add Jones Soda 4-packs, as well as the 12-count Variety Packs introduced earlier this year. "We had a strong relationship with Meijer from 2004 to 2016 when we had fewer flavors, fewer pack choices, and a much lower marketing profile than we have today," said Mark Murray, president and CEO of Jones Soda. "By restoring our presence in Meijer stores, this new agreement gives us an important channel for continuing to build our brand, helping us meet our growth targets, and positioning the company for long-term success." Initial shipments reached Meijer shelves this month, bringing Jones Soda to Meijer customers in Michigan, Illinois, Indiana, Kentucky, Ohio and Wisconsin.

Spero Therapeutics submits NDA to FDA for tebipenem HBr tablets 08:41 SPRO Spero Therapeutics announced the submission of a new drug application, or NDA, to the U.S. Food and Drug Administration, seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections, including pyelonephritis, caused by susceptible microorganisms. If approved, tebipenem HBr would be the only oral carbapenem antibiotic available for use in cUTI. "With the submission of this NDA, we have taken a major step towards potentially providing a substantial number of appropriate cUTI patients with an oral treatment option that could replace historical use of intravenous therapy," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. "If approved, we believe tebipenem HBr could help patients significantly, and the avoidance of IV administration could lead to reduced healthcare resource utilization. We look forward to working with the FDA during the NDA review process as we prepare for tebipenem HBr's anticipated launch in the second half of 2022."

JSDA-

SPRO-
 
stonedinvestor said:
Damn Damn Damn-- This is all I wanted GOED to do! Same story get on AMZN!!!// You might buy this as a lever in that direction but It's taken too long.

1847 Goedeker Inc. (GOED)
NYSE American - NYSE American Delayed Price. Currency in USD

3.1400+0.0300 (+0.96%)
At close: October 27 4:00PM EDT
3.1300-0.01 (-0.32%)
Pre-Market:08:52AM EDT
More...
They sell refrigerators, dishwashers, stoves, etc.
Nothing proprietary that a 1000 other merchants don't sell, via AMZN, EBAY, B&M, or any other channel.
Unlike my DGBI, they sell unique stuff.
 
--SeaSpine initiated with a Buy at Loop Capital 08:27 SPNE

--Perficient sees Q4 EPS 90c-93c, consensus 86c 08:15 PRFT Sees Q4 revenue $203M-$209M, consensus $196.16M.

PRFT GUMMY
 
vanzandt said:
They sell refrigerators, dishwashers, stoves, etc.
Nothing proprietary that a 1000 other merchants don't sell, via AMZN, EBAY, B&M, or any other channel.
Unlike my DGBI, they sell unique stuff.
More...


But everything everywhere is in such short supply. You can't buy alot of these things anywhere-- not at those outlets they are sold out. No merch I believe GOED has all the product because they are the LARGEST online place for all of this....

Buy yea ruin my thesis! Some day I'll tell you about the $9 stk I threw away that did this on AMZN and now sells for like $160.....!! Digital damn printing KORNIT OK I told You one of my all time bigest blunders.... KRNT.. Now I'm in a bad mod. Thanks Van....
 
Perficient reports Q3 EPS 88c, consensus 85c 08:13 PRFT Reports Q3 revenue $192.8M, consensus $190.11M. "Perficient's strong 2021 momentum continued in the third quarter and we expect additional strength during the fourth quarter as we close out the most robust year of growth in our history," said Jeffrey Davis, chairman and CEO. "The third quarter acquisition of Talos Digital, coupled with the recent addition of Overactive, added more than 800 talented developers, designers and digital innovators to our nearshore teams and further established Perficient as a truly global, next-generation service provider for the world's leading enterprises and biggest brands."

Vivid Seats initiated with a Buy at Canaccord 07:32 SEAT<----

There it is again that damn SPAC.
 
Imax reports Q3 adjusted EPS (8c) , consensus (13c) 07:25 IMAX Reports Q3 revenue $56.6M, consensus $56.42M. "Q3 was a major turning point for IMAX. We delivered over $142M in Global Box Office, a clear sign of significant pent up consumer demand with momentum accelerating into a pre-pandemic September performance and all-time company record in October, which is on track to be one of the top ten months in the company's history," said CEO Richard Gelfond. "The power of the IMAX theatrical window for blockbuster films is clear as we continue to draw moviegoers to the theaters, gain market share, and grow our relationships with local exhibitors, studios, and filmmakers. As anticipated, the domestic market continued its recovery with sequential growth in box office. Local language box office was also a strong performer which already eclipsed our record breaking 2019 local language box office. We are seeing greater confidence in the overall slate as well, as the IMAX-friendly franchise-heavy schedule has solidified through 2022. We feel confident that the table is set for a continued rebound in domestic and international blockbuster moviegoing which is reflected in our decision to opportunistically repurchase shares. With solid operating momentum, strong market share and multiple tentpole films set to be released in the remainder Q4 and 2022, IMAX is well positioned to deliver and strengthen our position as one of the world's premier entertainment experience."

That's What i call a Beat--Good Job Leon!

Mr. Cooper reports Q3 EPS $3.29, consensus $1.85 07:23 COOP Reports Q3 revenue $860M,
 
Carrier Global rasies FY21 adjusted EPS view to $2.20 from $2.10-$2.20 06:41 CARR Consensus $2.20. Raises FY21 revenue view to up 16% from up 14%-16%, consensus $20.32B. Guidance includes Chubb results.

YO GABA GABA!

WildBrain initiated with a Buy at Benchmark 06:37 WLDBF Benchmark analyst Daniel Kurnos initiated coverage of WildBrain with a Buy rating and C$6 price target, calling it "the last standalone public portfolio of premium quality kids' content." WildBrain has a library of about 500 brands and owns about a 40% stake in Peanuts, as well as other well-known titles such as Yo Gabba Gabba and Teletubbies, noted Kurnos, who expects the industry drive to migrate additional content behind paywalls to increase the value of WildBrain's intellectual property "and ultimately, we would suspect, leading to a takeout."

Cowen upgrades Teradyne to Outperform after share underperformance 06:28 TER, AAPL

Olin price target raised to $80 from $70 at Piper Sandler 06:02 OLN Piper Sandler analyst Charles Neivert raised the firm's price target on Olin to $80 from $70 and keeps an Overweight rating on the shares. The company has been executing on a strategic growth program and is already ahead of schedule, closing in on Phase 3, acquisition, Neivert tells investors in a research note. He says Olin's earnings easily beat Street estimates for Q3.

Stellantis backs FY21 adjusted operating income margin 10% 05:40 STLA Guidance assumes no further deterioration of semiconductor supply and no further significant lockdowns in Europe and U.S.

Scientific Games announces sale of Lottery business to Brookfield for $6.05B 20:08 SGMS, BBU
 
stonedinvestor said:
Imax reports Q3 adjusted EPS (8c) , consensus (13c) 07:25 IMAX Reports Q3 revenue $56.6M, consensus $56.42M. "Q3 was a major turning point for IMAX. We delivered over $142M in Global Box Office, a clear sign of significant pent up consumer demand with momentum accelerating into a pre-pandemic September performance and all-time company record in October, which is on track to be one of the top ten months in the company's history," said CEO Richard Gelfond. "The power of the IMAX theatrical window for blockbuster films is clear as we continue to draw moviegoers to the theaters, gain market share, and grow our relationships with local exhibitors, studios, and filmmakers. As anticipated, the domestic market continued its recovery with sequential growth in box office. Local language box office was also a strong performer which already eclipsed our record breaking 2019 local language box office. We are seeing greater confidence in the overall slate as well, as the IMAX-friendly franchise-heavy schedule has solidified through 2022. We feel confident that the table is set for a continued rebound in domestic and international blockbuster moviegoing which is reflected in our decision to opportunistically repurchase shares. With solid operating momentum, strong market share and multiple tentpole films set to be released in the remainder Q4 and 2022, IMAX is well positioned to deliver and strengthen our position as one of the world's premier entertainment experience."

That's What i call a Beat--Good Job Leon!

Mr. Cooper reports Q3 EPS $3.29, consensus $1.85 07:23 COOP Reports Q3 revenue $860M,
More...
I like IMAX.
$20.89
It'll drop a little, but its a good one going forward.
It gets the blessing.
 
You must log in or register to reply here.
Back
Top